LifeAssays® collaboration partner Abreos and the FDA in collaboration to develop method for measuring the concentration of active drug in blood.

Abreeos has previously announced (see link https://medtechinnovator.org/abreos-biosciences-announces-research-collaboration-with-fda-cder/) a research collaboration with the FDA to measure blood drug concentrations based on Veritope ™ technology. The Veritope™ technology is the basis of the collaboration in Aegirbio and the Company will commercialize.

The FDA's "Center for Drug Evaluation and Research (CDER)" has initiated a research collaboration with Abreos Biosciences to develop methods to measure biological drug concentrations in blood with high sensitivity and specificity. Abreo's platform Veritope ™ has the advantage of being able to quickly produce reagents that can be adapted to different analysis platforms, including clinical trials.

The goal of the FDA CDER and Abreo's joint development work is to evaluate new methods for measuring biological components where the FDA is particularly interested in methods that can be developed and validated quickly for regulatory purposes. The FDA has also identified a need in studies to characterize drug kinetics and efficacy. Being able to determine the concentration of biological drugs can result in safer and more efficient use of drugs in human medicine.

For additional information please contact the CEO of LifeAssays AB, Anders Ingvarsson 46 46 286 54 00 or email: info@lifeassays.com

About LifeAssays®. NGM-listed LifeAssays® ABs business idéa is to develop, manufature and sell diagnostic systems based on the Company proprietary and patented technology platform,  MagnetoImmunoAssay (MIA). The Company delivers safe and robust systems for quick and reliable analysis in human- and veterinay medicin. For more details please go to www.lifeassays.com